Redeye states that Eniro’s Q2 2025 report was slightly weaker across all items.
Redeye comments on Arise’s Q2 report, which saw higher production than expected, driving the segment...
Q2 details Infrea delivered a mixed report with higher sales and lower adj.
Redeye provides an initial comment on the Q2 2025 report from Tradedoubler, which showed solid growt...
Q2 details Sales SEK 427m (5% vs ABG 408m, -1% vs cons 421m).
Q2 details Sales were 2% above our expectations, with 7% organic sales growth (ABGSCe +4%), which in...
Q2 results Orders were up 12% y-o-y and 3% below our estimate.
Q2'25 outcome The Q2 report was above consensus' expectations.
Oriola posted strong growth figures in Q2, with net sales up 12% y/y and both segments showing doubl...
Consti's net sales in Q2 amounted to EUR 84.8m, surpassing our estimate (Evli est.
Tiratricol now has US FDA Breakthrough Therapy Designation for MCT8 deficiency, which is essential f...
Redeye provides its first take on Cellavision’s Q2 report 2025, published this morning.
Redeye comments on Annexin’s Q2 report and recent events in the company.
Redeye comments on the takeover offer on Bredband2 from Telia Company.
Q2 outcome Sales was SEK 2,395m (+2% vs. ABG 2,345m, +2% vs.
Redeye provides a short comment on the Q2 2025 report from Sdiptech, which came in below our estimat...
Redeye comments on Truecaller’s Q2 2025 report, which was somewhat softer than expected.
Redeye state Acconeer’s Q2 2025 report fell short of its expectations on both sales and EBITDA.
Redeye retains its positive view of Avensia despite slightly lowering our Base Case and forecasts.
Redeye comments on the negative topline data in the TRIFOUR study and provides a new base case.
